TEX Treatment for Metastatic Breast Cancer
Author Information
Author(s): Zakaria Einbeigi, D. Bergström, T. Hatschek, M. Malmberg
Primary Institution: Sahlgrenska University Hospital
Hypothesis
Is the combination of paclitaxel, epirubicin, and capecitabine a feasible first-line treatment for metastatic breast cancer?
Conclusion
The TEX regimen is a feasible and tolerable first-line treatment for metastatic breast cancer, showing promising response rates.
Supporting Evidence
- Nine patients (69%) achieved an objective response.
- Median time to progression was 6.6 months.
- Median overall survival was 23.5 months.
- Grade 3/4 adverse events were infrequent.
Takeaway
Doctors tested a new combination of three cancer drugs on 13 women with advanced breast cancer, and most of them got better.
Methodology
This was a non-comparative, open-label study assessing the safety and feasibility of the TEX regimen in women with untreated metastatic breast cancer.
Limitations
The study had a very small sample size and was not designed to determine efficacy.
Participant Demographics
{"median_age":50,"age_range":"43-65","ecog_performance_status":{"0":5,"1":8},"previous_therapy":{"radiotherapy":11,"hormonal_therapy":8,"adjuvant_chemotherapy":5}}
Statistical Information
Confidence Interval
{"median_time_to_progression":"6.6 months","median_overall_survival":"23.5 months"}
Want to read the original?
Access the complete publication on the publisher's website